← ANALYST RATINGS · TIPRANKS
InMode (INMD): analyst forecast and price target
Analyst consensus
Hold0 Buy3 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $15.00, the highest $15.00, the lowest $15.00. The average is +5.9% from the last price of $14.16.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Caitlin Roberts★★★★★★★★★★#1832 · hits 65% · avg +14.7% | Canaccord Genuity | $15.00 | Hold | +5.9% | Reiterated | 14.10.26on TipRanks 07:11 | +0.9%next day 0.0% | ↗ |
| Sam Eiber★★★★★★★★★★#4161 · hits 53% · avg +8.6% | BTIG | — | Hold | — | Reiterated | 13.10.26on TipRanks Oct 14 06:06 | 0.0%next day +0.9% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $17.50 → $16.50−5.7% | Buy | +16.5% | Reiterated | 07.09.26on TipRanks 02:10 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $16.50 → $15.50−6.1% | Hold | +9.5% | Reiterated | 07.09.26on TipRanks 02:10 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $17.00 → $16.50−2.9% | Buy | +16.5% | Reiterated | 07.09.26on TipRanks 02:10 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $15.50 | Hold | +9.5% | Reiterated | 07.09.26on TipRanks 02:10 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $17.00 → $16.00−5.9% | Hold | +13.0% | Downgrade | 07.09.26on TipRanks 02:10 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $17.00 | Buy | +20.1% | Reiterated | 07.09.26on TipRanks 02:10 | — | |
| Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% | Needham | — | Hold | — | Reiterated | 05.08.26on TipRanks 16:35 | −0.4%next day +0.6% · 5 days −0.7% | ↗ |
| Jeff Johnson★★★★★★★★★★#1125 · hits 51% · avg +10.4% | Robert W. Baird | $154 → $17.00−89.0% | Hold | +20.1% | Reiterated | 14.07.26on TipRanks 06:35 | −1.9%next day +2.0% · 5 days +3.4% | ↗ |
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $21.00 → $19.00−9.5% | Buy | +34.2% | Reiterated | 07.05.26on TipRanks 05:31 | +2.7%next day −0.5% · 5 days −1.3% | ↗ |
| Unknown Analyst | Jefferies | $15.00 | Hold | +5.9% | Reiterated | 14.04.26on TipRanks 16:40 | 0.0%next day +0.3% · 5 days −0.5% | ↗ |
| Danielle Antalffy★★★★★★★★★★#3190 · hits 51% · avg +3.3% | UBS | $16.25 → $16.00−1.5% | Hold | +13.0% | Reiterated | 06.11.25on TipRanks 08:35 | +0.5%next day 0.0% · 5 days −1.2% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering InMode
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 9 | 11 | 11 | 9 | 7 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.32 (from $0.28 to $0.34). Last quarter: $0.35.
Sales
Next quarter’s sales estimate — $92M (from $88M to $93M). Last quarter: $96M.
Best top-analyst consensus in the sector · Healthcare
About InMode
- CEO: Moshe Mizrahy
- Employees: 660
- Tavor Building, Yokne'am, TA, 2069206, IL
- www.inmodemd.com
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
Data from the stock’s TipRanks forecast page, read 138 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗